BREAKING
NVIDIA (NVDA) eyes China AI chip re-entry as export licensing shifts to case-by-case review 2 days ago Qualcomm (QCOM) authorizes $20B stock repurchase program, raises quarterly dividend to $0.92 2 days ago UP Fintech Holding Limited Reports Strong 2025 Results 2 days ago FedEx (FDX) Q3 Earnings Crush Estimates: EPS of $5.25 Beats by 27% on $24B Revenue 2 days ago Cato Corporation 2025 Financial Results Summary 2 days ago GROY Posts Breakeven Q4 Earnings, Beating Estimates by 100% as Revenue Grows 34.2% YoY to $4.5M 2 days ago York Space Systems (YSS) Posts -$0.24 EPS vs. -$0.18 Est., Revenue Soars to $105.3M 2 days ago Scholastic (SCHL) Q3 Loss Narrows to $0.15/Share vs $0.36 Estimate, Revenue Misses at $329.1M 2 days ago Curis (CRIS) EPS Soars 210.8% to $1.23, But Revenue Plunges 67.1% to $1.1M 2 days ago Eton Pharmaceuticals (ETON) Q4 Revenue Surges 82.9% YoY to $21.3M, EPS Climbs 266.7% 2 days ago NVIDIA (NVDA) eyes China AI chip re-entry as export licensing shifts to case-by-case review 2 days ago Qualcomm (QCOM) authorizes $20B stock repurchase program, raises quarterly dividend to $0.92 2 days ago UP Fintech Holding Limited Reports Strong 2025 Results 2 days ago FedEx (FDX) Q3 Earnings Crush Estimates: EPS of $5.25 Beats by 27% on $24B Revenue 2 days ago Cato Corporation 2025 Financial Results Summary 2 days ago GROY Posts Breakeven Q4 Earnings, Beating Estimates by 100% as Revenue Grows 34.2% YoY to $4.5M 2 days ago York Space Systems (YSS) Posts -$0.24 EPS vs. -$0.18 Est., Revenue Soars to $105.3M 2 days ago Scholastic (SCHL) Q3 Loss Narrows to $0.15/Share vs $0.36 Estimate, Revenue Misses at $329.1M 2 days ago Curis (CRIS) EPS Soars 210.8% to $1.23, But Revenue Plunges 67.1% to $1.1M 2 days ago Eton Pharmaceuticals (ETON) Q4 Revenue Surges 82.9% YoY to $21.3M, EPS Climbs 266.7% 2 days ago
ADVERTISEMENT
Market News

Abbott Laboratories: Solid product line expected to boost Q3 results

There are few pharmaceutical companies as solid as Abbott Laboratories (NYSE: ABT). Thanks to the two major acquisitions it made a couple of years ago – St. Jude Medical and Alere – the company currently has a strong and diversified product line. The stock has doubled in the past two years, and notably, the growth […]

October 11, 2019 2 min read
Market News

There are few pharmaceutical companies as solid as Abbott Laboratories (NYSE: ABT). Thanks to the two major acquisitions it made a couple of years ago – St. Jude Medical and Alere – the company currently has a strong and diversified product line. The stock has doubled in the past two years, and notably, the growth […]

There are few pharmaceutical companies as solid as Abbott Laboratories (NYSE: ABT). Thanks to the two major acquisitions it made a couple of years ago – St. Jude Medical and Alere – the company currently has a strong and diversified product line.

The stock has doubled in the past two years, and notably, the growth has been steady and consistent throughout this period.

Abbott will announce its third-quarter financial results on Wednesday, October 16, before the opening bell and the market is quite optimistic. Wall Street expects revenues to grow at a modest 6% to $8.11 billion, riding on the strong performance of the medical devices unit. The management had last quarter stated that it expects the pharmaceutical and diagnostics units also to improve in the second half of the financial year.

Abbott will next announce its third-quarter financial results on Wednesday, October 16

Analysts expect EPS to increase by 9 cents year-over-year to $0.84, in line with the company’s projection range of $0.83 to $0.85. Abbott views GAAP EPS between $0.53 and $0.55. The company has surpassed bottom-line estimates in two of the past four quarters while coming in line during the other two occasions.

Earlier this year, the Illinois-based firm had received FDA’s approvals for MitraClip G4, its fourth-generation heart valve repair device, and Alinity-S diagnostics system, a technology to screen and protect plasma supply. The market expects a positive impact from both these approvals in the current quarter results.

READ: Two zero-revenue biotech stocks debut in a shaky IPO market

Abbott’s ability to expand net income margins in line with the revenue increase, as well as the payout of earnings in the form of dividends make it even more attractive.

In Q2

Abbott’s second-quarter earnings topped estimates, while revenue came in line with the expectations.  The company had also lifted its earnings guidance for the full-year 2019, expecting to see some acceleration in the second half.

Abbott had projected full-year 2019 GAAP earnings to be between $2.06 to $2.12 per share. Adjusted EPS from continuing operations is predicted in the range of $3.21 to $3.27.

Browse through our earnings calendar
and get all scheduled earnings announcements, analyst/investor conference and
much more!

ADVERTISEMENT